Nebivolol Accord Healthcare

Nebivolol, the active ingredient in Nebivolol Accord Healthcare, is a beta‑blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors, enhances nitric‑oxide mediated vasodilation, and is used to manage high blood pressure and certain cardiac conditions, including essential hypertension and heart failure, in adult patients.

GNH USA supplies Nebivolol Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Nebivolol is a β1‑selective beta‑blocker indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

- Hypertension: lowers systolic and diastolic blood pressure to target ranges. - Chronic heart failure: improves left ventricular ejection fraction and reduces symptoms. - Left ventricular dysfunction: enhances ventricular performance and helps control related symptoms.

Nebivolol may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache - Dizziness or light‑headedness - Fatigue or tiredness - Nasal congestion

Serious or Rare Side Effects: - Bradycardia (abnormally slow heart rate) - Severe hypotension (dangerously low blood pressure) - Acute bronchospasm in patients with asthma

When prescribing nebivolol, clinicians should consider several safety measures.

- Dose adjustment: required in patients with severe renal or hepatic impairment. - Cardiovascular monitoring: watch for excessive heart‑rate reduction or hypotension. - Asthma caution: use with care in patients with reactive airway disease. - Concomitant drugs: avoid abrupt discontinuation of other antihypertensives. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Nebivolol interacts with several drug classes; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid): - Combined use with other β‑blockers: may cause profound bradycardia and hypotension. - Non‑selective calcium channel blockers (e.g., verapamil, diltiazem): increase nebivolol plasma levels. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): markedly raise nebivolol exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, monitor electrolytes. - Antidiabetic agents: nebivolol can mask hypoglycaemia symptoms, check glucose regularly. - NSAIDs: may reduce antihypertensive efficacy, observe blood pressure.